Timothy A Graubert

List of Publications by Year
in descending order

123	19,311	34105 52	25787 108
papers	citations	h-index	g-index

126	126	126	24738
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A synthetic small molecule stalls pre-mRNA splicing by promoting an early-stage U2AF2-RNA complex. Cell Chemical Biology, 2021, 28, 1145-1157.e6.	5.2	24
2	U2af1 is a haplo-essential gene required for hematopoietic cancer cell survival in mice. Journal of Clinical Investigation, 2021, 131, .	8.2	9
3	Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity. Molecular Cancer Therapeutics, 2021, 20, 2317-2328.	4.1	48
4	Spliceosome Mutant Myeloid Malignancies Are Preferentially Sensitive to PARP Inhibition. Blood, 2021, 138, 322-322.	1.4	4
5	Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study. Blood, 2021, 138, 1521-1521.	1.4	4
6	ATR/CHK1/WEE1 Dependency in SRSF2-Mutated MDS/AML. Blood, 2021, 138, 3661-3661.	1.4	1
7	A phase 1 study of the antibodyâ€drug conjugate brentuximab vedotin with reâ€induction chemotherapy in patients with CD30â€expressing relapsed/refractory acute myeloid leukemia. Cancer, 2020, 126, 1264-1273.	4.1	15
8	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e122-e133.	4.6	19
9	Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. Leukemia, 2020, 34, 3050-3054.	7.2	3
10	Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. Blood, 2020, 135, 1729-1738.	1.4	80
11	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	1.4	195
12	Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults. Blood, 2020, 136, 41-42.	1.4	1
13	Isocitrate dehydrogenase 1 and 2 mutations, 2â€hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer, 2019, 125, 541-549.	4.1	23
14	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	7.2	195
15	Redirecting T-Cells Against AML in a Multidimensional Targeting Space Using T-Cell Engaging Antibody Circuits (TEAC). Blood, 2019, 134, 2653-2653.	1.4	4
16	Targeting R-loop-associated ATR response in myelodysplastic syndrome. Oncotarget, 2019, 10, 2581-2582.	1.8	9
17	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nature Communications, 2018, 9, 455.	12.8	150
18	Genomics in childhood acute myeloid leukemia comes of age. Nature Medicine, 2018, 24, 7-9.	30.7	14

#	Article	IF	Citations
19	High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood, 2018, 131, 2816-2825.	1.4	64
20	Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. New England Journal of Medicine, 2018, 379, 2330-2341.	27.0	322
21	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. New England Journal of Medicine, 2018, 379, 1028-1041.	27.0	93
22	Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes. Cancer Research, 2018, 78, 5363-5374.	0.9	117
23	Pathobiology of Acute Myeloid Leukemia. , 2018, , 913-923.		1
24	Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight, 2018, 3, .	5.0	48
25	Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia. Blood, 2018, 132, 766-766.	1.4	9
26	Clinical Outcomes Following Frontline Chemotherapy for Patients with Myeloid Malignancies Harboring Splicing Factor Mutations. Blood, 2018, 132, 4364-4364.	1.4	0
27	Single-Cell RNA-Seq Reveals AML Cellular Hierarchies Relevant to Clinical Outcomes and Immunity. Blood, 2018, 132, 542-542.	1.4	0
28	Potential Barriers to Clinical Trials of New Therapeutics for Myelodysplastic Syndromes: Wide Variation in Risk Definitions and Trial Enrollment Criteria. Blood, 2018, 132, 4378-4378.	1.4	0
29	Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nature Communications, 2017, 8, 14060.	12.8	99
30	Functions of Replication Protein A as a Sensor of R Loops and a Regulator of RNaseH1. Molecular Cell, 2017, 65, 832-847.e4.	9.7	205
31	Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica, 2017, 102, 719-727.	3.5	33
32	Splicing factor gene mutations in hematologic malignancies. Blood, 2017, 129, 1260-1269.	1.4	99
33	Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia. JCO Precision Oncology, 2017, 1, 1-7.	3.0	3
34	Prevalence and complications associated with off-label use of lenalidomide in older patients with myelodysplastic syndromes (MDS).. Journal of Clinical Oncology, 2017, 35, 7054-7054.	1.6	0
35	Case 37-2016. New England Journal of Medicine, 2016, 375, 2273-2282.	27.0	3
36	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	16.8	227

#	Article	IF	Citations
37	Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood, 2016, 127, 893-897.	1.4	94
38	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036.	27.0	663
39	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Experimental Hematology, 2016, 44, 603-613.	0.4	44
40	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood, 2015, 126, 2484-2490.	1.4	207
41	Health care utilization and endâ€ofâ€life care for older patients with acute myeloid leukemia. Cancer, 2015, 121, 2840-2848.	4.1	113
42	Patterns and functional implications of rare germline variants across 12 cancer types. Nature Communications, 2015, 6, 10086.	12.8	243
43	Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. Cancer, 2015, 121, 951-959.	4.1	157
44	Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing InÂVivo. Cancer Cell, 2015, 27, 631-643.	16.8	259
45	Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nature Biotechnology, 2015, 33, 646-655.	17.5	130
46	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Molecular Diagnostics, 2015, 17, 661-668.	2.8	31
47	Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA - Journal of the American Medical Association, 2015, 314, 811.	7.4	302
48	Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature, 2015, 518, 552-555.	27.8	685
49	New Molecular Abnormalities and Clonal Architecture in AML: From Reciprocal Translocations to Whole-Genome Sequencing. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e334-e340.	3.8	10
50	SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution. PLoS Computational Biology, 2014, 10, e1003665.	3.2	400
51	Clonal Architecture of Secondary Acute Myeloid Leukemia Defined by Single-Cell Sequencing. PLoS Genetics, 2014, 10, e1004462.	3.5	115
52	A Call to Action for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1064-1066.	27.0	11
53	Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 379-392.	16.8	330
54	Integrated analysis of germline and somatic variants in ovarian cancer. Nature Communications, 2014, 5, 3156.	12.8	253

#	Article	IF	Citations
55	Pathogenic Variants for Mendelian and Complex Traits in Exomes of 6,517 European and African Americans: Implications for the Return of Incidental Results. American Journal of Human Genetics, 2014, 95, 183-193.	6.2	78
56	AML Genomics for the Clinician. Seminars in Hematology, 2014, 51, 322-329.	3.4	6
57	AML Genomics: Introduction. Seminars in Hematology, 2014, 51, 249.	3.4	1
58	Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice. Blood, 2014, 124, 3887-3895.	1.4	20
59	Prognostic understanding, quality of life (QOL), and mood in patients undergoing hematopoietic stem cell transplantation (HCT).. Journal of Clinical Oncology, 2014, 32, 219-219.	1.6	4
60	Allele-Specific Effects Of U2AF1 Mutations On Alternative Splicing. Blood, 2013, 122, 2748-2748.	1.4	0
61	Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature Genetics, 2012, 44, 53-57.	21.4	513
62	Imputation of Exome Sequence Variants into Population- Based Samples and Blood-Cell-Trait-Associated Loci in African Americans: NHLBI GO Exome Sequencing Project. American Journal of Human Genetics, 2012, 91, 794-808.	6.2	123
63	Clonal Architecture of Secondary Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 1090-1098.	27.0	688
64	Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 2012, 481, 506-510.	27.8	1,795
65	The Origin and Evolution of Mutations in Acute Myeloid Leukemia. Cell, 2012, 150, 264-278.	28.9	1,365
66	Mutant U2AF1(S34F) Expression Alters Hematopoiesis in Mice. Blood, 2012, 120, 553-553.	1.4	0
67	Genetics of Myelodysplastic Syndromes: New Insights. Hematology American Society of Hematology Education Program, 2011, 2011, 543-549.	2.5	49
68	Genomics of Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass), 2011, 17, 487-491.	2.0	20
69	Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene. JAMA - Journal of the American Medical Association, 2011, 305, 1577.	7.4	233
70	Identification of a Novel <emph type="ital">TP53</emph> Cancer Susceptibility Mutation Through Whole-Genome Sequencing of a Patient With Therapy-Related AML. JAMA - Journal of the American Medical Association, 2011, 305, 1568.	7.4	146
71	Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. Journal of Clinical Investigation, 2011, 121, 1445-1455.	8.2	91
72	Complete Sequencing and Comparison of 12 Normal Karyotype M1 AML Genomes with 12 t(15;17) Positive M3-APL Genomes. Blood, 2011, 118, 404-404.	1.4	1

#	Article	IF	Citations
73	Integrated genomics of susceptibility to alkylator-induced leukemia in mice. BMC Genomics, 2010, 11, 638.	2.8	5
74	Therapy-Related Myelodysplastic Syndrome: Models and Genetics. Biology of Blood and Marrow Transplantation, 2010, 16, S45-S47.	2.0	11
75	DNMT3AMutations in Acute Myeloid Leukemia. New England Journal of Medicine, 2010, 363, 2424-2433.	27.0	1,777
76	Molecular basis of hematology. , 2010, , 1-26.		0
77	DNA Sequence of the Cancer Genome of a Patient with Therapy-Related Acute Myeloid Leukemia. Blood, 2010, 116, 580-580.	1.4	0
78	Mutations In the DNA Methyltransferase Gene DNMT3A Are Highly Recurrent In Patients with Intermediate Risk Acute Myeloid Leukemia, and Predict Poor Outcomes. Blood, 2010, 116, 99-99.	1.4	9
79	Recurrent DNMT3A Mutations In Patients with Myelodysplastic Syndrome. Blood, 2010, 116, 608-608.	1.4	0
80	Detection of Novel Mutations In MDS/AML by Whole Genome Sequencing. Blood, 2010, 116, 299-299.	1.4	0
81	Murine Models of Human Acute Myeloid Leukemia. Cancer Treatment and Research, 2009, 145, 183-196.	0.5	16
82	Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Research and Treatment, 2009, 118, 593-598.	2.5	41
83	The impact of copy number variation on local gene expression in mouse hematopoietic stem and progenitor cells. Nature Genetics, 2009, 41, 430-437.	21.4	112
84	Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome. New England Journal of Medicine, 2009, 361, 1058-1066.	27.0	2,009
85	Next-generation sequencing of cancer genomes: back to the future. Personalized Medicine, 2009, 6, 653-662.	1.5	26
86	Acquired copy number alterations in adult acute myeloid leukemia genomes. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12950-12955.	7.1	231
87	Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood, 2009, 113, 5575-5582.	1.4	93
88	BRCA1 and BRCA2 Nucleotide Variants in Young Women with Therapy Related Acute Myeloid Leukemia.. Blood, 2009, 114, 1102-1102.	1.4	5
89	Integrated Genomic Analysis Implicates Haploinsufficiency of Multiple Chromosome 5q31.2 Genes in De Novo Myelodysplastic Syndromes Pathogenesis. PLoS ONE, 2009, 4, e4583.	2.5	48
90	POU4F1 Is Associated with t(8;21) AML and Contributes Directly to Its Unique Transcriptional Signature.. Blood, 2009, 114, 2623-2623.	1.4	6

#	Article	IF	Citations
91	DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature, 2008, 456, 66-72.	27.8	1,275
92	Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood, 2008, 111, 4809-4812.	1.4	84
93	wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data. Nucleic Acids Research, 2008, 36, e41.	14.5	25
94	Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood, 2008, 111, 4797-4808.	1.4	198
95	Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice. Blood, 2008, 112, 1434-1442.	1.4	11
96	AML1 and Evi1: coconspirators in MDS/AML?. Blood, 2008, 111, 3916-3917.	1.4	0
97	Bcl2, a Candidate Murine Therapy-Related Acute Myeloid Leukemia Susceptibility Factor, Exhibits Strain-Dependent and Alkylator-Responsive Expression.. Blood, 2008, 112, 1499-1499.	1.4	0
98	A High-Resolution Map of Segmental DNA Copy Number Variation in the Mouse Genome. PLoS Genetics, 2007, 3, e3.	3.5	196
99	A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 1201-1206.	2.0	24
100	Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood, 2007, 110, 1648-1655.	1.4	88
101	Comprehensive Genomic Copy Number and Sequence Analysis of 28 Chromosome 5q31.2 Candidate Genes in De Novo MDS.. Blood, 2007, 110, 117-117.	1.4	1
102	Identification of Polymorphisms Associated with Susceptibility to Therapy-Related MDS and AML.. Blood, 2007, 110, 15-15.	1.4	5
103	A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.. Blood, 2007, 110, 1451-1451.	1.4	1
104	Pharmacogenetics of alkylator-associated acute myeloid leukemia. Pharmacogenomics, 2006, 7, 719-729.	1.3	10
105	Identification of Candidate Alkylator-Induced Cancer Susceptibility Genes by Whole Genome Scanning in Mice. Cancer Research, 2006, 66, 5029-5038.	0.9	44
106	Phase II Trial of the Tyrosine Kinase Inhibitor PKC412 in Advanced Systemic Mastocytosis: Preliminary Results.. Blood, 2006, 108, 3609-3609.	1.4	2
107	Roles of Sca-1 in hematopoietic stem/progenitor cell function. Experimental Hematology, 2005, 33, 836-843.	0.4	108
108	Dominant Negative Effects of the AML1/ETO Fusion Oncoprotein. Cell Cycle, 2005, 4, 33-36.	2.6	4

#	Article	IF	Citations
109	Sca-1 negatively regulates proliferation and differentiation of muscle cells. Developmental Biology, 2005, 283, 240-252.	2.0	96
110	A Mouse Model of Alkylator-Induced Myelodysplastic Syndrome.. Blood, 2005, 106, 368-368.	1.4	17
111	A high resolution map of segmental DNA copy number variation in the mouse genome. PLoS Genetics, 2005, preprint, e3.	3.5	0
112	A Randomized, Double Blind Trial, of Hydroxychloroquine for the Prevention of Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation.. Blood, 2005, 106, 1800-1800.	1.4	0
113	Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15184-15189.	7.1	81
114	Recruitment of Bone Marrow-Derived Endothelial Cells to Sites of Pancreatic Â-Cell Injury. Diabetes, 2004, 53, 91-98.	0.6	172
115	Enhanced green fluorescent protein targeted to the Sca-1 (Ly-6A) locus in transgenic mice results in efficient marking of hematopoietic stem cells in vivo. Experimental Hematology, 2003, 31, 159-167.	0.4	47
116	Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. British Journal of Haematology, 2003, 123, 110-113.	2.5	28
117	A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14275-14280.	7.1	55
118	A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. Journal of Applied Physiology, 2003, 95, 1352-1360.	2.5	27
119	Sca-1pos Cells in the Mouse Mammary Gland Represent an Enriched Progenitor Cell Population. Developmental Biology, 2002, 245, 42-56.	2.0	491
120	Characterization of Ly-6M, a novel member of the Ly-6 family of hematopoietic proteins. Blood, 2000, 95, 3125-3132.	1.4	19
121	Granzyme A Initiates an Alternative Pathway for Granule-Mediated Apoptosis. Immunity, 1999, 10, 595-605.	14.3	140
122	How do cytotoxic lymphocytes kill their targets?. Current Opinion in Immunology, 1998, 10, 581-587.	5.5	353
123	Recombinant retroviral systems for the analysis of drug resistant HIV. Nucleic Acids Research, 1993, 21, 4836-4842.	14.5	17